Compare CLDI & FEED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLDI | FEED |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.1M |
| IPO Year | 2021 | 2014 |
| Metric | CLDI | FEED |
|---|---|---|
| Price | $1.60 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 260.7K |
| Earning Date | 05-14-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $45,000.00 | ★ $318,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.09 | $0.29 |
| 52 Week High | $5.12 | $6.09 |
| Indicator | CLDI | FEED |
|---|---|---|
| Relative Strength Index (RSI) | 76.29 | 51.58 |
| Support Level | $1.17 | $0.29 |
| Resistance Level | $1.62 | $0.97 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 81.49 | 91.06 |
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
ENvue Medical Inc is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. It focuses on two technology platforms: the ENvue Navigation Platform, which provides an electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract; FDA 510(k) cleared for adult use, it provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Its Medical advances non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation in healthcare environments, and the company's acoustic-based therapeutic technologies.